MARIPOSA: First-Line Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC

May 3, 2024

By Joshua K. Sabari, MD
Helena A. Yu, MD

Opinion

Video

Focusing on the MARIPOSA trial, the panel provides thoughts the potential role of amivantamab and lazertinib, and discusses treatment decisions upon progression.

EP: 1.Biomarker Testing in Non–Small Cell Lung Cancer

EP: 2.NSCLC: Molecular Testing in the Metastatic Setting

EP: 3.NGS Testing Challenges and Considerations in NSCLC

EP: 4.Frontline Treatment for EGFR-Mutated Lung Cancer

EP: 5.FLAURA2: Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

Now Viewing

EP: 6.MARIPOSA: First-Line Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC

EP: 7.Second-Line Treatment of Patients With EGFR-Mutated NSCLC

EP: 8.Treatment Landscape for NSCLC With EGFR Exon 20 Insertion Mutations

EP: 9.NSCLC with EGFR Exon 20 Insertions: Updated Data from PAPILLON

EP: 10.Unmet Needs and Future Perspectives on the Treatment of EGFR-Mutated NSCLC

EP: 11.Preferred Treatment Options for EGFRMutated Exon 20 Insertion+ NSCLC

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!